



Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Pape	work Reduction Act of 18	195, no persons are	required to respond to a collection of information unless it co	ntains a valid OMB control number	1PA
		ORMA	PA/PTO FION DISCLOSURE OF BY APPLICANT	Application Number 0 1 P	if Known
	(use as ma	ny sheets as necessary)	Filing Date (7)	November 12, 2000
				First Named Inventor	M. Rignon Lentz
				Group Art Unit	
				Examiner Name	
Sheet	1	of	3	Attorney Docket Number	LEN 102

		· · · · · · · · · · · · · · · · · · ·	U.S. PATENT DOCU	· · · · · · · · · · · · · · · · · · ·	
Examiner Initials*	Cite US Patent Document No.1		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code (if know			
712		4,708,713	Lentz	11-24-1987)
		5,135,919	Folkman et al.	08-04-1992	
		5,147,638	Esmon et al.	09-15-1992	
		5,290,807	Folkman et al.	03-01-1994	
		5,629,327	D'Amato	05-13-1997	
		5,639,725	O'Reilly et al.	06-17-1997	
		5,698,586	Kishimoto et al.	12-16-1997	
		5,712,291	D'Amato	06-27-1998	
		5,713,491	Hughes et al.	02-03-1998	7
		5,716,981	Hunter et al.	02-10-1998	/
V		5,733,876	O'Reilly et al.	03-31-1998	
			- 		

				F	OREIGN PATENT DOCUMENT	S				
Examiner Initials*	Cite No.¹			Foreign Patent Document			1	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number⁴	Kind Code ⁵ (if known)			· · · · · · · · · · · · · · · · · · ·			
-										
		<u> </u>		_1		<u> </u>		<u> </u>		

Examine Signature	9 8e L S	مد		Date Considered	15	١,	<u>, l c</u>	57	
Signature	V	- X -	-	Considered		10	4		
		$\overline{}$				_	,_		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.



Part Type PTOISB/08A (10-98
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known Application Number 09/709,045 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) November 12, 2000 Filing Date First Named Inventor M. Rignon Lentz **Group Art Unit** 1647 J. sehaverseyon **Examiner Name** 2 of 3 Attorney Docket Number **LEN 102** Sheet

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
xaminer's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Τ²
٠-٩٢		ANDREWS, et al., "Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin LT) on human T lymphocytes: TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma," <i>J Immunol</i> 144:2582-2591 (1990).	J
		CHEN, et al., "Soluble TNF-a receptors are constitutively shed and downgregulate adhesion molecule expression in malignant gilomas," <i>J. Neuropathol. Exp. Neurol.</i> 56(5):541-550 (1997).	-
		CLACKSON, et al., "Making antibody fragments using phage display libraries," Nature 352:624-688 (1991).	
		DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a, murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19:2471-2476 (1991).	•
		EY, et al., "Isolation of pure IgG_1 , IgG_{2a} , and IgG_{2b} . immunoglobulins from mouse serum using protein A-Sepharose," <i>Immunochemistry</i> 15:429-436 (1978).	
		FEINMAN, et al., "Tumor necrosis factor is a important mediator of tumor cell killing by human monocytes," J Immunol 138:635 (1987).	
		GATANAGA, et al., "Identification of TNF-LT blocking factor(s) in the serum and ultrafiltrates of human cancer patients," <i>Lymphokine Res</i> 9:225-9 (1990).	
		HARANAKA, et al, "Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro," <i>Jpn J Exp Med</i> 51:191 (1981).	
		Hemostasis and Thrombosis: Basic Principles and Clinical Practice 2nd Ed., Colman, R.W., et al.,p. 263 (J.B.Lippincott, Philadelphia, PA 1987).	
		HOWARD, et al., "Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family," <i>Virology</i> 180:633-664 (1991).	

Examiner's Date 15 2107	
Signature Considered Consi	1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

1334856v1

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE Application Numbe 09/709,045 STATEMENT BY APPLICANT MAR 0 8 2001 (use as many sheets as necessary) Filing Date November 12, 2000 First Named Inventor M. Rignon Lentz **Group Art Unit** 1647 J. seravaseyon Examiner Name 3 Sheet of 3 **Attorney Docket Number LEN 102**

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
xaminer's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		JABLONSKA & PEITRUSKA, "Release of soluble tumor necrosis factor receptors from polymorphoniclear cells of breast cancer parients," <i>Arch. Immunol. Ther. Exp.</i> (Warsz) 45(5-6)449-453 (1997).	
		KABAT, et al., <u>Sequences of Proteins of Immunological Interest</u> 4 th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD, 1987).	
		LANGKOPF, et al., "Soluble tumor necrosis factor receptors as prognostic factors in cancer patients," <i>Lancet</i> 344:57-58 (1994).	
		MATHIAS, et al., "Activation of the Sphingomyelin signaling pathway intact EL4 cells and in a cell-free system by IL-lb," <i>Science</i> 259:519-522 (1993).	_
		MATSCHINER, et al., <u>Current Advances in Vitamin K Research</u> , pp. 135-140, John W. Suttie, ed. (Elsevier Science Publishing Co., Inc. 1988).	
		OLD, Antitumor activity of microbial products and tumor necrosis factor, and Bonavida B, et al., (eds): Tumor Necrosis Factor/Cachecin and Related Cytokines, Basell, Karger, p7 (1988).	
		PHILIP, et al., "Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, Gamma-interferon and Interleukin-1," <i>Nature</i> 323:86 (1986).	
		URBAN, et al., "Tumor necrosis factor: A potent effector molecule for tumor cell killing by activated macrophages," Proc Natl Acad Sce USA 83:5233 (1986).	
		ZIEGLER-HEITBROCK, et al., "Tumor necrosis factor as effector molecule in monocyte-mediated cytotoxicity," Cancer Res 46:5947 (1986).	

Signature	<u></u>	Je h	2	Date Considered	10	12	or_	
	J					1		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

i	
	1
ı	

		and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Meditie Premork Reduction Act of 1995, no persons are required to respond to a collect	tion of information unless it contains a valid OME	control number
Substitute for form 1449A/PTO	Con	mplete if Known
WINFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/709,045
	Filing Date	November 10, 2000
COPY OF PAPERS	First Named Inventor	M. Rigdon Lentz
ORIGINALLY FILED	Group Art Unit	1647
	Examiner Name	J. Seharaseyon.
Sheat 4 of 2	Attorney Docket Number	LEN 102

Cite No. ¹	US Pa	itent Doci	ıment	Nome of						
raminer Cite US Patent Document No.1			Name of Patentee or Applicant of Cited Document			Date of Cited Document MM-DD-YYYY	F	ages, Columns, Lines, Where Releva Passages or Relevant Figures Appea	int ir	
	Number		Code 2					ĺ		
	 	(11	Known)	-	····	+		├		
			 			\forall	/	 		
						1				
				·····	/_			\mathbf{R}	CEIVED	
			+-+					1		
								M	AR = 4 2002	
				/_						
							7.	CH	FNTER 1600/2900	
		_/						ULLS	VEITI -	
		·				+				
					OREIGN PATENT DOCL	IMEN	TS			
Cite		Foreign	Patent Doc		Name of Patentee or			tion of	Pages, Columns, Lines, Where	T
No.1			Applicant of Cited Docum		nent			Relevant Passages or Relevant	ĺ	
Ī	Office.3	N	umber ⁴	Kind Code⁵	1		00-1111	ł	rigures Appear	l
	MO	00/6409	· · · · · · · · · · · · · · · · · · ·							_
	wo	99/0100	13		Lentz		12-02-1999			
				_						_
								-		
	lo. ¹	Cite Io.1 Office.3	Cite Foreign Office. 3 No	(if known) Cite Foreign Patent Documents of the Control of the Co	(if known) (if known) (if known) (ite Foreign Patent Document Kind Code ⁵ (if known)	FOREIGN PATENT DOCL ite Foreign Patent Document Name of Patentee or Applicant of Cited Document Office. Office. Number Kind Code (if known)	FOREIGN PATENT DOCUMEN Site lo.¹ Office.³ Number⁴ Kind Code³ (if known) WO 99/61085 A Lentz	FOREIGN PATENT DOCUMENTS Site 10.1	FOREIGN PATENT DOCUMENTS THICH (THIC	FOREIGN PATENT DOCUMENTS TECH CENTER 1600/2900 Tech Center 1600/29

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

	a plus sign to insid		+ popersons are required to respond to	o a collection of information unless it contains a	PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
TRADE	Substitute for	form 1449	A/PTO		Complete if Known RECEIVED
	STATE	MENT	N DISCLOSURE BY APPLICANT heets as necessary)	Application Number	09/709,045 MAR - 4 2002 TECH CENTER 1600/2900
COPYC	FPAPERS			Filing Date	November 10, 2000
ORIGINA	ALLY FILED			First Named Inventor	M. Rigdon Lentz
				Group Art Unit	1647
				Examiner Name	J. severaseyon
Sheet	2	of	2	Attorney Docket Number	LEN 102
			OTUED ADT		

xaminer's I	Cite	OTHER ART – NON PATENT LITERATURE DOCUMENTS				
Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T			
ZZ	GATANAGA, et al., "Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tunecrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients," Proceedings of National Academy of the USA 87(22):8781-87814 (1990).					
\		LENTZ, "Continuous whole blood UltraPheresis procedure in patients with metastatic cancer," Journal of Biological Response Modifiers 8(5):511-527 (1989).	-			
		LENTZ, "The role of therapeutic apheresis in the treatment of cancer: a review," Therapeutic Apheresis 3(1):40-49 (1999).				
		SELINSKY, et al., "Multifaceted inhibition of anti-tumor immune mechanisms by soluble tumour necrosis factor receptor type-1," <i>Immunology</i> 94(1):88-93 (1998).				
7		TETTA, et al., "Continuous plasma filtration coupled with sorbents," Kidney International 53(66):S186-S189 (1998).				
aminer's		Date Considered 57.1.00	<u></u>			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

OIP	Please upon plus sign (+) inside this bo	ox → +
~ n'	2 2002 (5)	

Please the part of the Part o	Patent ar	PTO/SB/08A (10- Approved for use through 10/31/99. OMB 0651-00 and Trademark Office: U.S. DEPARTMENT OF COMMERC
TRASCLIRITA	1	nplete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/709,045
	Filing Date	November 10, 2000
	First Named Inventor	M. Rigdon Lentz
·	Group Art Unit	1647
Sheet 1 of 1	Examiner Name	J. Senovaloepon.
Srieet 1 of 1	Attorney Docket Number	LEN 102

5	6:-		U.S. PATENT DOCU	MENTS		
Examiner Initials*	Cite No. ¹	US Patent Document Number Kind Code (if known	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
ক্য		6,379,708	Howell, et al.	04-30-2002		
					RECEIVED	
					SEP 0 4 2002	
					TECH CENTER 1600/2900	

Examiner Initials*	Cite No.1	Foreign Patent Document			OREIGN PATENT DOCUMEN Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Relevant Passages or Relevant	T
		Office.3	Number ⁴	Kind Code ⁵ (if known)		DD-TTTY	Figures Appear	
								
								<u> </u>
				1 - 1				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

18/16/02

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language